APOA1 and myocardial infarction: Finally, with regards to anti-apoA-1 IgG and CV disease and mortality (19, 20, 22), FCRL3 mRNA levels have been reported to be downregulated in patients with myocardial infarction when compared to those with stable angina or healthy subjects (50), suggesting that FCRL3-mediated immune dysregulation may also be involved in atheromatous plaque instability and rupture.